10th World Congress on Neuropharmacology August 28-29, 2018 Paris, France

Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/MDPI journals. Photon Advisory Board Member. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress. Inc). Scientist for Science Advisory Board (USA) and Academic with Academia.edu. H-index of 43, (ResearchGate STATs (23), Mendeley STATS (20). Scientific research citations accumulated to >3300. Lifetime Membership by International Agency for Standards and Ratings as Fellow. Winner (World Academic Championship -2017) in Diabetes and Medical Science (Nutrition). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM.

Prevalent chronic diseases such as cardiovascular disease, non alcoholic fatty liver disease (NAFLD) and neurodegenerative diseases that includes epilepsy induced stroke have raised major concern with relevance to diabetes and the global problem for chronic diseases. The need to optimize drug therapy and improve therapeutic outcomes has become of major concern with relevance to alarming reports of drug-drug interactions or drug-protein interactions. The role of various factors such as diet, environment, stress and lifestyle as important factors that regulate drug therapy and stabilize insulin resistance is relevant to chronic diseases. Research that involves the various factors and inactivation of anti-aging genes have indicated relevance to defective drug metabolism. The heat shock gene Sirtuin 1 (Sirt 1) and its repression inactivates insulin therapy, hepatic drug metabolism and antimicrobial therapy. Sirt 1 inhibitors are connected to mitophagy and induction of NAFLD linked to food quality and pharmacological management (antimicrobial/antiepileptic therapy). Drugs such as Avasimibe reverse NAFLD and improve pharmacological management in NAFLD and chronic diseases.